[CAS NO. 78246-49-8] Paroxetinehydrochloride

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [78246-49-8]

Catalog

HY-B0492

Brand

MCE

CAS

78246-49-8

DESCRIPTION [78246-49-8]

Overview

MDL	MFCD00797405
Molecular Weight	365.83
Molecular Formula	C19H21ClFNO3
SMILES	FC1=CC=C([C@H]2[C@H](COC3=CC=C(OCO4)C4=C3)CNCC2)C=C1.Cl

For research use only. We do not sell to patients.

4 Publications Citing Use of MCE

Summary

Paroxetine hydrochloride is a potent selective serotonin-reuptake inhibitor, commonly prescribed as an GRK2 inhibitor with IC ₅₀ of 14 μM. Paroxetine hydrochloride can be used for the research of depressive disorder ^[1] ^[2] ^[3] .

IC50 & Target

IC50: 14 μM (GRK2) ^[3]

In Vitro

Paroxetine (1 μM and 10 μM) distinctly restrains T cell migration induced by CX3CL1 through inhibiting GRK2. Paroxetine inhibits GRK2 induced activation of ERK ^[1] . Paroxetine (10 μM) reduces pro-inflammatory cytokines in LPS-stimulated BV2 cells. Paroxetine (0-5 μM) leads to a dose-dependent inhibition on LPS-induced production of TNF-α and IL-1β in BV2 cells. Paroxetine also inhibits lipopolysaccharide (LPS)-induced nitric oxide (NO) production and inducible nitric oxide synthase (iNOS) expression in BV2 cells. Paroxetine (5 μM) blocks LPS-induced JNK activation and attenuates baseline ERK1/2 activity in BV2 cells. Paroxetine relieves microglia-mediated neurotoxicity, and suppresses LPS-stimulated pro-inflammatory cytokines and NO in primary microglial cells ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Paroxetine treatment obviously attenuates the symptoms of CIA rats. Paroxetine treatment clearly prevents the histological damage of joints and alleviates T cells infiltration into synovial tissue. Paroxetine reveals a strong effect on inhibiting CX3CL1 production in synovial tissues ^[1] . Paroxetine (20 mg/kg/day) reduces the myocyte cross-sectional area in rat and ROS formation in the remote myocardium. Paroxetine reduces the susceptibility to ventricular tachycardia. Paroxetine treatment following MI decreases LV remodeling and susceptibility to arrhythmias, probably by reducing ROS formation ^[2] . In CCI paroxetine-treated group, paroxetine (10 mg/kg, i.p.) produces hyperalgesia at days 7 and 10 (P<0.01), but a decrease in pain behavior is seen at day 14. Moreover, paroxetine (10 mg/kg) significantly attenuates tactile hypersensitivity when compared to CCI vehicle-treated group ^[5] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01602913	GlaxoSmithKline	Depression, Postpartum	December 2011
NCT05175430	University Hospital, Basel, Switzerland	Healthy	October 24, 2022	Phase 1
NCT02279966	H. Lundbeck A+S	Major Depressive Disorder	October 2014	Phase 3
NCT02655354	University of Washington\|National Institutes of Health (NIH)\|National Institute of Mental Health (NIMH)\|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Posttraumatic Stress Disorder\|Depression\|Alcohol-Related Disorders\|Suicidal Ideation\|Substance-Related Disorders\|Mild Cognitive Impairment\|Quality of Life\|Pain\|Wounds and Injury\|Brain Injuries\|Chronic Disease	October 2015	Not Applicable
NCT00136383	Duke University\|GlaxoSmithKline	Depressive Symptoms	March 2005	Phase 2\|Phase 3
NCT00420641	GlaxoSmithKline	Depressive Disorder	December 19, 2006	Phase 2
NCT02097147	Forest Laboratories	Healthy	March 2014	Phase 1
NCT00086190	University of Rochester\|National Institute of Neurological Disorders and Stroke (NINDS)	Parkinson Disease\|Depression	June 2005	Phase 3
NCT00397722	GlaxoSmithKline	Social Phobia	November 9, 2006	Phase 2
NCT04757571	Sadat City University	Rheumatoid Arthritis	February 1, 2021	Phase 1\|Phase 2
NCT01024491	MorePharma Corporation	Premature Ejaculation	August 2008	Phase 3
NCT00516113	Karolinska Institutet\|Novo Nordisk A+S\|GlaxoSmithKline\|Göteborg University	Premenstrual Dysphoric Disorder\|Premenstrual Syndrome	October 2000	Phase 4
NCT01289756	Robert Bosch Gesellschaft für Medizinische Forschung mbH	Anovulation\|Disorder Due Cytochrome P450 CYP2D6 Variant\|Cytochrome P450 CYP3A Enzyme Deficiency	December 2009	Phase 1
NCT01916200	GlaxoSmithKline	Depressive Disorder	January 2014	Phase 4
NCT01841502	Radboud University Medical Center\|Janssen, LP	Hepatitis C Infection\|Depression	May 2013	Phase 2
NCT00400088	Nova Scotia Health Authority	Major Depressive Disorder	June 2007	Phase 3
NCT00292370	VA Office of Research and Development\|AstraZeneca	Combat Disorders\|Stress Disorders, Post-Traumatic	January 2006	Phase 4
NCT04650542	HUYABIO International, LLC.	Drug-drug Interaction	February 21, 2021	Phase 1
NCT00178100	University of Pittsburgh	Unipolar Depression	March 1999	Phase 4
NCT00629551	Sanofi	Depressive Disorder, Major	February 2008	Phase 3
NCT00648427	Mylan Pharmaceuticals Inc\|MylanPharma	Healthy	April 2005	Phase 1
NCT00062738	Rutgers, The State University of New Jersey\|GlaxoSmithKline	Parkinson Disease\|Depression	June 2003	Phase 2
NCT01681849	Emory University\|National Institute of Mental Health (NIMH)	PTSD	July 2009	Phase 4
NCT00785603	University of Southern Denmark	Depression\|Pain	August 2008	Phase 4
NCT00177567	University of Pittsburgh	Bipolar Disorder	July 2001	Phase 4
NCT02174822	Otsuka Pharmaceutical Development & Commercialization, Inc.	Drug-drug Interaction	January 2014	Phase 1
NCT00836069	Cedars-Sinai Medical Center\|Pfizer	Anxiety Disorders	October 2008	Phase 3
NCT00351910	AstraZeneca	Major Depressive Disorder	May 2006	Phase 3
NCT01000857	GlaxoSmithKline	Depressive Disorder	November 5, 2009	Phase 1
NCT00100464	US Department of Veterans Affairs\|VA Office of Research and Development	Obstructive Sleep Apnea	November 2000	Phase 4
NCT00018759	US Department of Veterans Affairs\|SmithKline Beecham\|VA Office of Research and Development	Depression\|Hypertension	March 2001	Phase 4
NCT00938184	GlaxoSmithKline	Depressive Disorder	July 14, 2009	Phase 1
NCT00610909	Duke University\|GlaxoSmithKline	Irritable Bowel Syndrome	January 2002	Phase 4
NCT00650403	Mylan Pharmaceuticals Inc\|MylanPharma	Healthy	December 2006	Phase 1
NCT00715039	Pfizer	Anxiety Disorders	October 2003	Not Applicable
NCT00074802	Temple University\|National Institute of Mental Health (NIMH)	Social Anxiety Disorder	December 2003	Phase 3
NCT00209118	Emory University	Hepatitis C\|Depression\|Interferon-alpha Associated Side Effects		Not Applicable
NCT00196664	French National Agency for Research on AIDS and Viral Hepatitis	Chronic Hepatitis C	October 2005	Phase 3
NCT00385762	Weill Medical College of Cornell University	Healthy	January 2007
NCT00067444	GlaxoSmithKline	Depressive Disorder, Major\|Major Depressive Disorder (MDD)	June 2003	Phase 3
NCT00540098	University of Göttingen\|GlaxoSmithKline	Panic Disorder	September 2001	Phase 4
NCT00048204	GlaxoSmithKline	Depressive Disorder, Major	November 4, 2002	Phase 2
NCT00901407	Louisiana State University Health Sciences Center in New Orleans\|GlaxoSmithKline	Unipolar Depression	December 2003	Not Applicable
NCT01371461	GlaxoSmithKline	Mental Disorders	January 2004
NCT03274752	University Hospital Inselspital, Berne	Cardiac Remodeling\|Myocardial Infarction	October 26, 2017	Phase 2
NCT00025740	National Institute of Mental Health (NIMH)\|National Institutes of Health Clinical Center (CC)	Post Traumatic Stress Disorder	October 2001	Phase 4
NCT00736346	Université du Québec a Montréal\|Canadian Institutes of Health Research (CIHR)	Panic Disorder\|Anxiety Disorder\|Mental Disorder	October 2005	Not Applicable
NCT00594269	Sykehuset Innlandet HF\|Ullevaal University Hospital\|Eikertun Nursing Home\|University of Bergen\|Innlandet Hospital Trust, Sanderud\|Innlandet Hospital Trust, Reinsvoll\|Diakonhjemmet Hospital\|Sykehuset Telemark\|The Nordmøre and Romsdal Hospital Trust\|Songdalstunet Nursing Home\|Sykehuset Buskerud HF\|Kroken Nursing Home, Tromsø\|Kløveråsen, Bodø\|Bjørgene Omsorgssenter, Haugesund\|Alesund Hospital	Dementia	August 2008	Phase 4
NCT02852577	Universidade Federal do Rio de Janeiro\|Conselho Nacional de Desenvolvimento Científico e Tecnológico	Panic Disorder\|Agoraphobia	January 2000	Phase 4
NCT00658762	Pfizer	Generalized Anxiety Disorder	May 2008	Phase 3
NCT00463242	Novartis	Major Depressive Disorder	March 2007	Phase 3
NCT00330239	Medical University of South Carolina\|GlaxoSmithKline	PTSD	January 2003	Phase 4
NCT00403455	VA Office of Research and Development	PTSD	October 2006	Phase 3
NCT00620581	Hamilton Health Sciences Corporation\|McMaster University	Premenstrual Dysphoric Disorder		Phase 3
NCT04207723	Boston Medical Group	Premature Ejaculation	February 2020	Not Applicable
NCT00445679	Wyeth is now a wholly owned subsidiary of Pfizer	Depressive Disorder, Major	July 2007	Phase 3
NCT00672776	Emory University	Posttraumatic Stress Disorder (PTSD)	May 2003	Phase 4
NCT02237937	HolsboerMaschmeyer NeuroChemie GmbH\|Max-Planck-Institute of Psychiatry	Major Depression	September 2011	Phase 4
NCT00700999	US Department of Veterans Affairs\|VA Office of Research and Development	Post-traumatic Stress Disorder	October 2008	Phase 4
NCT01049347	Central Institute of Mental Health, Mannheim	Unipolar Depression	October 1997	Phase 3
NCT04404439	University of California, Irvine	Tinnitus, Subjective\|Tinnitus	September 26, 2019	Phase 4
NCT02273154	Si Tianmei\|Peking University	Major Depression Disorder	August 2014	Phase 4
NCT00647881	Mylan Pharmaceuticals Inc\|MylanPharma	Healthy	April 2005	Phase 1
NCT00322595	AstraZeneca	Generalized Anxiety Disorder	May 2006	Phase 3
NCT03054220	Jules Desmeules\|University Hospital, Geneva	Healthy	July 2016	Not Applicable
NCT03504475	Beijing Tongren Hospital\|Beijing Winsunny Pharmceutical Co.,Ltd.	Major Depressive Disorder\|Obsessive-Compulsive Disorder\|Panic Disorder\|Social Anxiety Disorder\|Generalized Anxiety Disorder	March 29, 2018	Phase 1
NCT04218981	Central South University	Common Mental Disorder	January 15, 2020	Not Applicable
NCT00035009	Merck Sharp & Dohme LLC	Major Depressive Disorder	September 20, 2001	Phase 3
NCT00012558	National Institute of Mental Health (NIMH)	Bipolar Disorder	September 1998	Not Applicable
NCT00841659	Teva Pharmaceuticals USA	Healthy	August 2002	Phase 1
NCT00368303	GlaxoSmithKline	Depressive Disorder, Major\|Major Depressive Disorder (MDD)	December 2006	Phase 3
NCT00456560	Avigen	Healthy	April 2007	Phase 1
NCT03277339	Centre Hospitalier Henri Laborit\|Association Francaise pour la Recherche Thermale\|Les thermes de Saujon\|Poitiers University Hospital\|Centre National de la Recherche Scientifique (CeRCA, umr 7295), France	Generalized Anxious Disorders	January 19, 2017	Phase 4
NCT00879099	Santen Oy	Healthy	April 2009	Phase 1
NCT00489775	Eli Lilly and Company	Major Depressive Disorder	January 2004	Phase 3
NCT04981704	Spectrum Pharmaceuticals, Inc	Healthy	April 8, 2021	Phase 1
NCT00677352	Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.\|Pfizer	Panic Disorder	May 2008	Phase 4
NCT00406432	GlaxoSmithKline	Depressive Disorder	May 9, 2006	Phase 1
NCT01371448	GlaxoSmithKline	Mental Disorders	May 2001
NCT00839397	GlaxoSmithKline	Post-Traumatic Stress Disorder	May 2002	Phase 3
NCT02681198	USWM, LLC (dba US WorldMeds)\|National Institute on Drug Abuse (NIDA)	Healthy	January 2016	Phase 1
NCT00178048	University of Pittsburgh\|GlaxoSmithKline	Primary Insomnia\|Depression	September 1998	Phase 4
NCT00318669	GlaxoSmithKline	Social Phobia	December 2005	Phase 3
NCT00825058	Sanofi	Major Depressive Disorders	November 2003	Phase 3
NCT01748955	New York State Psychiatric Institute\|National Institute of Mental Health (NIMH)	Depression\|Suicidal Ideation	June 2010	Phase 4
NCT01416220	Nova Scotia Health Authority	Major Depressive Disorder	September 2011	Phase 4
NCT01896349	Hospital de Clinicas de Porto Alegre	Treatment Resistant Depression	April 2013	Not Applicable
NCT00191022	Eli Lilly and Company	Social Phobia	December 2004	Phase 2
NCT00119652	AstraZeneca	Bipolar Disorder\|Bipolar Depression\|Depression	May 2005	Phase 3
NCT00357045	Portland VA Medical Center\|GlaxoSmithKline\|Schering-Plough	Major Depression		Phase 4
NCT03894085	Central South University	Anxiety Disorder\|Obsessive-Compulsive Disorder	May 30, 2019	Not Applicable
NCT04446039	Pfizer	Major Depression	July 4, 2022
NCT01130103	Research Foundation for Mental Hygiene, Inc.\|National Institute of Mental Health (NIMH)	Posttraumatic Stress Disorder	March 2004	Phase 4
NCT00261729	US Department of Veterans Affairs\|VA Office of Research and Development	Sleep Disorders\|Stress Disorders, Post-Traumatic	July 2004	Not Applicable
NCT00329147	Wyeth is now a wholly owned subsidiary of Pfizer	Depression	May 2006	Phase 3
NCT00178035	University of Pittsburgh	Depression	December 1999	Phase 4
NCT02320240	Canadian Network for Observational Drug Effect Studies, CNODES\|Drug Safety and Effectiveness Network, Canada\|Canadian Institutes of Health Research (CIHR)	Depression\|Acute Kidney Injury	June 2013
NCT01376271	GlaxoSmithKline	Social Phobia	January 2010
NCT00206765	Beth Israel Medical Center	Major Depressive Disorder With Panic Attacks\|Panic Disorder	January 2003	Phase 2
NCT01354314	Johns Hopkins University\|National Institute of Mental Health (NIMH)	HIV Associated Neurocognitive Disorder	November 2010	Phase 1\|Phase 2
NCT00034983	Merck Sharp & Dohme LLC	Major Depressive Disorder	October 29, 2001	Phase 3
NCT00073203	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Major Depressive Disorder		Phase 2
NCT02022709	Shanghai Mental Health Center\|Shanghai Municipal Science and Technology Commission\|Shanghai Jiao Tong University School of Medicine	Obsessive-Compulsive Disorder\|Anxiety Disorders\|Mental Disorders	January 2014	Phase 4
NCT03538691	Otsuka Pharmaceutical Development & Commercialization, Inc.	Major Depressive Disorder	July 13, 2018	Phase 3
NCT05470465	Food and Drug Administration (FDA)\|Spaulding Clinical Research LLC\|Leiden University	Hypercapnia\|Ventilatory Depression	September 1, 2022	Phase 1
NCT00135525	GlaxoSmithKline	Anxiety Disorder\|Anxiety Disorders	May 2003	Phase 2
NCT04311463	GlaxoSmithKline	Anxiety Disorders	December 9, 2020	Phase 1
NCT03149419	Rio de Janeiro State University	Postmenopausal Flushing\|Cardiovascular Risk Factor\|Endothelial Dysfunction	March 1, 2016	Phase 4
NCT00113295	Massachusetts General Hospital	Anxiety Disorder	February 2004	Phase 4
NCT00384020	National Health Research Institutes, Taiwan\|National Science Council, Taiwan\|Chang Gung Memorial Hospital\|Taipei Medical University WanFang Hospital\|Taipei City Hospital\|Mackay Memorial Hospital	Depression	January 2006
NCT01360866	Otsuka Pharmaceutical Development & Commercialization, Inc.	Depressive Disorder\|Depression\|Depressive Disorder, Major\|Mood Disorders\|Mental Disorders	October 2011	Phase 3
NCT00658008	Pfizer	Generalized Anxiety Disorder	April 2008	Phase 3
NCT00812812	GlaxoSmithKline	Depressive Disorder	March 2009	Phase 4
NCT00246441	Medical University of South Carolina\|National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Social Anxiety Disorder\|Social Phobia\|Alcohol Use Disorder\|Alcohol Abuse\|Alcohol Dependence	March 2002	Phase 4
NCT00658372	Pfizer	Generalized Anxiety Disorder	May 2008	Phase 3
NCT00338962	Yale University	Alcoholism\|Depression\|PTSD	October 2001	Phase 3
NCT02374567	Hannover Medical School	Dementia\|Depression\|Schizophrenia\|Psychosomatic Disorders\|Anxiety Disorders	January 2015	Phase 3
NCT00825019	Sanofi	Major Depressive Disorders	September 2003	Phase 3
NCT02932904	Takeda	Healthy Volunteers	November 21, 2016	Phase 4
NCT00641173	US Department of Veterans Affairs\|Emory University\|VA Office of Research and Development	Post-Traumatic Stress Disorders	September 2008	Not Applicable
NCT00557622	GlaxoSmithKline	Post-Traumatic Stress Disorder\|Stress Disorders, Post-Traumatic	January 25, 2008	Phase 2
NCT00273039	GlaxoSmithKline	Social Anxiety Disorder\|Anxiety Disorders	August 2005	Phase 2
NCT01367535	Bausch Health Americas, Inc.	Healthy Adults	March 2006	Phase 1
NCT01458626	Capital Medical University	Major Depression	November 14, 2012	Phase 4
NCT00406003	GlaxoSmithKline	Depressive Disorder	March 24, 2006	Phase 1
NCT00374166	Sanofi	Anxiety Disorders	August 2006	Phase 2
NCT00018733	US Department of Veterans Affairs\|VA Office of Research and Development	Depression	September 1996	Not Applicable
NCT00492414	Inje University\|GlaxoSmithKline	Panic Disorder		Phase 4
NCT00519012	Oizumi Hospital	Depression	August 2007	Phase 4
NCT00866294	GlaxoSmithKline	Depressive Disorder	April 2009	Phase 3
NCT03779789	Azienda Ospedaliera Universitaria Integrata Verona\|University of Catania	Major Depressive Disorder	February 1, 2019	Phase 4
NCT02893371	University of New Mexico\|Patient-Centered Outcomes Research Institute\|Montana State University\|National Alliance on Mental Illness Montana\|CGStat LLC\|Risk Benefit Statistics LLC\|National Alliance on Mental Illness New Mexico\|National Alliance on Mental Illness Westside Los Angeles	Bipolar Disorder	September 2016
NCT03329573	GlaxoSmithKline	Anxiety Disorders	May 30, 2018	Phase 1
NCT00225914	Massachusetts General Hospital\|GlaxoSmithKline	Menopause	September 2004	Phase 4
NCT00259883	GlaxoSmithKline	Mental Disorders	June 2005	Phase 4
NCT04888728	Daewoong Pharmaceutical Co. LTD.	Idiopathic Pulmonary Fibrosis	June 30, 2021	Phase 1
NCT00048607	Merck Sharp & Dohme LLC	Major Depressive Disorder	July 30, 2002	Phase 3
NCT02451475	Mansoura University	Fibromyalgia	February 2013	Phase 1\|Phase 2
NCT01371474	GlaxoSmithKline	Panic Disorder	April 2006
NCT00202449	Seattle Institute for Biomedical and Clinical Research\|United States Department of Defense\|VA Puget Sound Health Care System	Stress Disorders, Post-Traumatic\|Sleep Disorders	July 2004	Not Applicable
NCT00195598	Wyeth is now a wholly owned subsidiary of Pfizer	Panic Disorders	January 2005	Phase 3
NCT03879746	Assiut University	Premature Ejaculation	April 2019	Phase 3
NCT00456898	Wyeth is now a wholly owned subsidiary of Pfizer	Depressive Disorder, Major\|Diabetic Neuropathies\|Fibromyalgia\|Vasomotor Symptoms	January 2007	Phase 1
NCT02264184	Boehringer Ingelheim	Healthy	September 2008	Phase 1
NCT05188833	Istanbul Medipol University Hospital	Obsessive-Compulsive Disorder\|EEG With Periodic Abnormalities	May 17, 2020	Not Applicable
NCT00429169	New York State Psychiatric Institute\|National Institute of Mental Health (NIMH)	Depression	June 2004	Phase 4
NCT00049972	GlaxoSmithKline	Major Depressive Disorder	September 2002	Phase 4
NCT00394056	GlaxoSmithKline	Tinnitus	December 2006	Phase 2
NCT02191124	Capital Medical University	Major Depressive Disorder	June 2011	Phase 4
NCT04188028	Jules Desmeules\|University Hospital, Geneva	Healthy	January 1, 2019	Not Applicable
NCT00457106	Beth Israel Medical Center	Major Depression With Panic Attacks\|Panic Disorder	June 2002	Not Applicable
NCT00666757	Eli Lilly and Company\|Boehringer Ingelheim	Depression	May 2008	Phase 4
NCT00470483	GlaxoSmithKline	Social Phobia	January 22, 2007	Phase 1
NCT00648193	Mylan Pharmaceuticals Inc\|MylanPharma	Healthy	December 2006	Early Phase 1
NCT00264654	GlaxoSmithKline	Social Phobia	October 2005	Phase 3
NCT00000368	New York State Psychiatric Institute\|National Institute of Mental Health (NIMH)	Panic Disorder\|Agoraphobia	February 1999	Phase 3
NCT00291148	University of Manitoba	Neuropathic Pain\|Multiple Sclerosis	March 2006	Phase 3
NCT01376128	GlaxoSmithKline	Panic Disorder	March 2008
NCT01371435	GlaxoSmithKline	Mental Disorders	April 2001
NCT00031317	National Institute of Mental Health (NIMH)\|National Institutes of Health Clinical Center (CC)	Panic Disorder	February 2002	Phase 4
NCT00343707	GlaxoSmithKline	Depressive Disorder and Anxiety Disorders	November 2004	Phase 2
NCT00249847	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Hot Flashes	October 2005	Not Applicable
NCT00560612	Durham VA Medical Center	Stress Disorders, Post-Traumatic	January 2006	Phase 4
NCT00665678	Foundation for Atlanta Veterans Education and Research, Inc.\|Emory University	Posttraumatic Stress Disorder (PTSD)	April 2008	Phase 4
NCT04961190	University of Pennsylvania\|Patient-Centered Outcomes Research Institute\|Corporal Michael J. Crescenz VA Medical Center\|Coatesville VA Medical Center\|Milwaukee VA Medical Center\|North Texas Veterans Healthcare System\|San Diego Veterans Healthcare System\|VA Palo Alto Health Care System	Posttraumatic Stress Disorder	May 25, 2022	Phase 4
NCT01764867	Shanghai Mental Health Center	Major Depressive Disorder	June 2012	Phase 4
NCT00926835	Ministry of Health & Welfare, Korea	Major Depressive Disorder	May 2009	Phase 4
NCT00218439	University of Minnesota\|National Institute on Drug Abuse (NIDA)	Tobacco Use Disorder	October 2005	Not Applicable
NCT00610610	Duke University\|GlaxoSmithKline	Fibromyalgia Syndrome	January 2002	Phase 4
NCT00841698	Teva Pharmaceuticals USA	Healthy	October 2002	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 273.35 mM ; Need ultrasonic)

H ₂ O : 5 mg/mL ( 13.67 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7335 mL	13.6676 mL	27.3351 mL
5 mM	0.5467 mL	2.7335 mL	5.4670 mL
10 mM	0.2734 mL	1.3668 mL	2.7335 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (6.83 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (6.83 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.83 mM); Clear solution
4.

Add each solvent one by one: PBS

Solubility: 2.03 mg/mL (5.55 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

Synonyms

Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, hydrochloride (1:1), (3S,4R)-

Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, hydrochloride, (3S-trans)-

Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, hydrochloride, (3S,4R)-

Paroxetine hydrochloride

BRL 29060 hydrochloride

BRL 29060A

Paxil

(-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine hydrochloride

Seroxat

Aropax 20

Tagonis

Deroxat

Paroxet

Xanadol